127 related articles for article (PubMed ID: 37942683)
21. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.
Warbey VS; Ferner RE; Dunn JT; Calonje E; O'Doherty MJ
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):751-7. PubMed ID: 19142634
[TBL] [Abstract][Full Text] [Related]
22. False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1.
Shahid KR; Amrami KK; Esther RJ; Lowe VJ; Spinner RJ
J Surg Orthop Adv; 2011; 20(2):132-5. PubMed ID: 21838076
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive anatomical and functional imaging in patients with type I neurofibromatosis using simultaneous FDG-PET/MRI.
Reinert CP; Schuhmann MU; Bender B; Gugel I; la Fougère C; Schäfer J; Gatidis S
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):776-787. PubMed ID: 30535768
[TBL] [Abstract][Full Text] [Related]
24. New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications.
Marjanska A; Galazka P; Wysocki M; Styczynski J
Anticancer Res; 2020 Apr; 40(4):1817-1831. PubMed ID: 32234870
[TBL] [Abstract][Full Text] [Related]
25. [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.
Tsai LL; Drubach L; Fahey F; Irons M; Voss S; Ullrich NJ
J Neurooncol; 2012 Jul; 108(3):469-75. PubMed ID: 22407214
[TBL] [Abstract][Full Text] [Related]
26. Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging.
Well L; Salamon J; Kaul MG; Farschtschi S; Herrmann J; Geier KI; Hagel C; Bockhorn M; Bannas P; Adam G; Mautner VF; Derlin T
Neuro Oncol; 2019 Mar; 21(4):508-516. PubMed ID: 30496452
[TBL] [Abstract][Full Text] [Related]
27. Value of PET in the assessment of patients with neurofibromatosis type 1.
Bredella MA; Torriani M; Hornicek F; Ouellette HA; Plamer WE; Williams Z; Fischman AJ; Plotkin SR
AJR Am J Roentgenol; 2007 Oct; 189(4):928-35. PubMed ID: 17885067
[TBL] [Abstract][Full Text] [Related]
28. Plurifocal malignant peripheral nerve sheath tumor demonstrated by 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Bertagna F; Bosio G; Biasiotto G; Savelli G; Rodella C; Giubbini R; Rosenbaum J; Alavi A
Jpn J Radiol; 2009 Oct; 27(8):320-3. PubMed ID: 19856228
[TBL] [Abstract][Full Text] [Related]
29. Foreign Body Abscess Mimicking a Malignant Peripheral Nerve Sheath Tumor in a Patient With Neurofibromatosis Type 1.
Salamon J; Hagel C; Friedrich RE; Mautner VF; Derlin T
Clin Nucl Med; 2015 Aug; 40(8):674-5. PubMed ID: 26018702
[TBL] [Abstract][Full Text] [Related]
30. Limitations and benefits of FDG-PET/CT in NF1 patients with nerve sheath tumors: A cross-sectional/longitudinal study.
Nishida Y; Ikuta K; Ito S; Urakawa H; Sakai T; Koike H; Ito K; Imagama S
Cancer Sci; 2021 Mar; 112(3):1114-1122. PubMed ID: 33415792
[TBL] [Abstract][Full Text] [Related]
31. Ipsilateral and contralateral thalamic hypometabolism as a predictor of outcome after temporal lobectomy for seizures.
Newberg AB; Alavi A; Berlin J; Mozley PD; O'Connor M; Sperling M
J Nucl Med; 2000 Dec; 41(12):1964-8. PubMed ID: 11138679
[TBL] [Abstract][Full Text] [Related]
32. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.
Brenner W; Friedrich RE; Gawad KA; Hagel C; von Deimling A; de Wit M; Buchert R; Clausen M; Mautner VF
Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):428-32. PubMed ID: 16404595
[TBL] [Abstract][Full Text] [Related]
33. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.
Moharir M; London K; Howman-Giles R; North K
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1309-17. PubMed ID: 20179923
[TBL] [Abstract][Full Text] [Related]
34. Malignant transformation to schwannoma in a patient affected by type 1 neurofibromatosis as demonstrated by F-18-FDG-PET/CT.
Bertagna F; Bosio G; Biasiotto G; Fisogni S; Bercich L; Giubbini R
Nucl Med Rev Cent East Eur; 2010; 13(1):15-7. PubMed ID: 21154311
[TBL] [Abstract][Full Text] [Related]
35. Peripheral nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphologic variants.
Agaimy A; Märkl B; Kitz J; Wünsch PH; Arnholdt H; Füzesi L; Hartmann A; Chetty R
Virchows Arch; 2010 Apr; 456(4):411-22. PubMed ID: 20155280
[TBL] [Abstract][Full Text] [Related]
36. The value of 18F-FDG PET/CT in patient with neurofibromatosis type 1: A case report and literature review.
Ren J; Yang G; Zhou J; Fu Z
Medicine (Baltimore); 2018 May; 97(20):e10648. PubMed ID: 29768331
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of
Geitenbeek RTJ; Martin E; Graven LH; Broen MPG; Anten MHME; van der Pol JAJ; Verhoef C; Taal W
J Neurooncol; 2022 Feb; 156(3):559-567. PubMed ID: 35025020
[TBL] [Abstract][Full Text] [Related]
38. Multiparametric whole-body anatomic, functional, and metabolic imaging characteristics of peripheral lesions in patients with schwannomatosis.
Ahlawat S; Baig A; Blakeley JO; Jacobs MA; Fayad LM
J Magn Reson Imaging; 2016 Oct; 44(4):794-803. PubMed ID: 26991037
[TBL] [Abstract][Full Text] [Related]
39. Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.
Uthoff J; De Stefano FA; Panzer K; Darbro BW; Sato TS; Khanna R; Quelle DE; Meyerholz DK; Weimer J; Sieren JC
J Neuroradiol; 2019 May; 46(3):179-185. PubMed ID: 29958847
[TBL] [Abstract][Full Text] [Related]
40. Management of peripheral nerve sheath tumors: 17 years of experience at Toronto Western Hospital.
Guha D; Davidson B; Nadi M; Alotaibi NM; Fehlings MG; Gentili F; Valiante TA; Tator CH; Tymianski M; Guha A; Zadeh G
J Neurosurg; 2018 Apr; 128(4):1226-1234. PubMed ID: 28686119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
